A Phase I Dose-Escalation Study of OSI-906 and Erlotinib (Tarceva) in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2016
At a glance
- Drugs Erlotinib; Linsitinib
- Indications Solid tumours
- Focus Adverse reactions
- 01 Feb 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 21 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Apr 2011 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov.